ZOMDF Zomedica Corp.
Pharmaceutical Preparations · OTC · SEC CIK 1684144 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.3%
TTM net income YoY81.1%
TTM EPS YoY88.9%
Revenue 3-yr CAGR17.2%
Net income 3-yr CAGR—
Margins
Gross margin64.0%
Operating margin-45.4%
Net margin-41.4%
FCF margin-30.8%
EBITDA margin-40.0%
Returns
ROE-14.3%
ROA-13.0%
ROIC (approx.)-13.3%
Asset turnover0.31x
Leverage & solvency
Liabilities / assets9.3%
Debt / equity0.00x
Current ratio6.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-3.7%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20222021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $32.03M | $27.29M | $25.19M | $18.93M | $4.13M |
| Cost of revenue | $10.35M | $8.20M | $7.87M | $5.46M | $1.08M |
| Gross profit | $21.68M | $19.09M | $17.32M | $13.47M | $3.05M |
| R&D expense | $7.17M | $7.27M | $5.74M | $2.58M | $1.67M |
| SG&A expense | $24.50M | $29.66M | $29.03M | $22.93M | $22.75M |
| Operating income | -$84.35M | -$51.05M | -$43.27M | -$21.92M | -$21.37M |
| Interest expense | — | — | $175,000 | $1,000 | $6,000 |
| Pretax income | -$82.14M | -$47.54M | -$35.86M | -$19.38M | -$20.72M |
| Income tax | -$278,000 | -$557,000 | -$1.33M | -$2.37M | -$2.33M |
| Net income | -$81.86M | -$46.98M | -$34.53M | -$17.02M | -$18.38M |
| EBITDA | -$82.30M | -$49.51M | -$42.45M | -$21.50M | -$21.11M |
| EPS (basic) | -0.08 | -0.05 | -0.04 | -0.02 | -0.05 |
| EPS (diluted) | -0.08 | -0.05 | -0.04 | -0.02 | -0.05 |
| Weighted avg. shares (diluted) | 979.95M | 979.95M | 979.95M | 979.95M | 956.53M |
| Balance sheet | |||||
| Cash & equivalents | $9.02M | $7.02M | $12.95M | $27.40M | $194.95M |
| Receivables | $3.01M | $2.42M | $1.20M | $596,000 | $315,000 |
| Inventory | $5.54M | $5.06M | $5.12M | $2.75M | $2.85M |
| Current assets | $64.04M | $81.77M | $99.88M | $123.50M | $200.41M |
| PP&E, net | $20.91M | $24.59M | $22.83M | $6.81M | $1.13M |
| Goodwill | $0 | $45.56M | $61.58M | $63.98M | $43.29M |
| Intangibles | $38.81M | $52.54M | $55.36M | $41.80M | $33.18M |
| Total assets | $127.04M | $207.36M | $253.20M | $279.61M | $280.40M |
| Current liabilities | $9.45M | $9.33M | $9.03M | $7.81M | $4.34M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $11.64M | $11.70M | $13.18M | $12.22M | $9.51M |
| Shareholders' equity | $115.40M | $195.66M | $240.02M | $267.39M | $270.89M |
| Shares outstanding | 979.95M | 979.95M | 979.95M | 979.95M | 979.90M |
| Cash flow statement | |||||
| Operating cash flow | -$17.65M | -$23.63M | -$15.97M | -$11.67M | -$14.28M |
| Capital expenditure | $567,000 | $5.21M | $11.34M | $787,000 | $147,000 |
| Free cash flow | -$18.22M | -$28.84M | -$27.31M | -$12.46M | -$14.42M |
| Investing cash flow | $19.57M | $17.85M | $1.58M | -$155.88M | -$71.92M |
| Financing cash flow | — | -$70,000 | — | $8,000 | $219.16M |
| Depreciation & amortization | $2.06M | $1.54M | $830,000 | $426,000 | $265,000 |
| Stock-based compensation | $2.47M | $2.78M | $6.26M | $7.89M | $7.09M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.